Form 4: Avidity Biosciences CTO Sells Shares for Tax Obligations

Avidity Biosciences' Chief Technical Officer, Charles Calderaro III, sold 3,727 shares of common stock at $72.23 per share to cover tax withholding obligations related to RSU vesting.

Summary

• Charles Calderaro III, Chief Technical Officer of Avidity Biosciences, Inc. (RNA), reported a sale of company common stock.
• The transaction involved the disposition of 3,727 shares of Avidity Biosciences common stock on January 7, 2026.
• The shares were sold at a price of $72.23 per share.
• This sale was a 'sell-to-cover' transaction, mandated by the company's equity incentive plans to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 6, 2026.
• The transaction was not a discretionary trade by Mr. Calderaro and was executed under an instruction letter intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Mr. Calderaro beneficially owns 49,797 shares of Avidity Biosciences common stock.

Sentiment

Score: 5

Explanation: Neutral, as the transaction is a routine, non-discretionary sale for tax purposes, not indicative of management's discretionary view on the company's prospects or a change in investment sentiment.

Future Outlook

This filing reports a past transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction related to equity compensation and tax obligations, common across all industries for executives of publicly traded companies. It does not provide specific insights into broader industry trends or competitive landscape.

Corporate Governance

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine, non-discretionary tax-related sale, which does not typically signal a change in management's confidence or the company's operational performance.

Key Dates

Recommendation

The reported transaction is a routine 'sell-to-cover' sale by a Chief Technical Officer to satisfy tax obligations upon RSU vesting, executed under a Rule 10b5-1 plan. This is a non-discretionary event and does not reflect a change in the insider's view of the company's future prospects. Therefore, it provides no new fundamental information to warrant a change in investment recommendation.

Keywords

Avidity Biosciences, RNA, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Rule 10b5-1, Charles Calderaro III